New hope for multiple myeloma: early trial of HDP-101 begins in china

NCT ID NCT07529782

Recruiting now Disease control Sponsor: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Apr 15, 2026 · Last updated May 13, 2026 · Updated 2 times

Summary

This early-stage study tests a new drug called HDP-101 in 15 Chinese patients with multiple myeloma, a type of blood cancer. The goal is to find a safe dose and see if the drug can shrink tumors. Participants must have tried other treatments first.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA AND OTHER PLASMA CELL NEOPLASMS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Beijing Chao-Yang Hospital, Capital Medical University
RECRUITING

Beijing, Beijing Municipality, 100020, China
Institute of Hematology & Blood Diseases Hospital,Chinese Academy of Medical Sciences
RECRUITING

Tianjin, Tianjin Municipality, 300020, China
Qilu Hospital of Shandong University
RECRUITING

Jinan, Shandong, 250012, China
The First Affiliated Hospital of Soochow University
RECRUITING

Suzhou, Jiangsu, 215006, China
The First Affiliated Hospital, Zhejiang University School of Medicine
NOT_YET_RECRUITING

Hangzhou, Zhejiang, 310003, China

Conditions

Explore the condition pages connected to this study.

MULTIPLE MYELOMA AND OTHER PLASMA CELL NEOPLASMS